AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29532635
Drug: Gels rich
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gels rich in precursors (glucoraphanin and glucoiberin)
Trial: 21940695
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections to parotid and submandibular glands (5 individuals)
Trial: 21940695
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injections to submandibular glands only (1 individual)
Trial: 20227758
Drug: Mipomersen 200
RxNorm normalized name: mipomersen 200 mg/mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mipomersen 200 mg subcutaneously every week for 26 weeks
Trial: 14523294
Drug: 1-week-on, 1-week-off
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-week-on, 1-week-off therapy
Trial: 14523294
Drug: Triple nucleotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple nucleotide therapy
Trial: 1458665
Drug: 5% amorolfine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% amorolfine nail lacquer, once-weekly
Trial: 1458665
Drug: 5% amorolfine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% amorolfine nail lacquer, twice-weekly
Trial: 25527663
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (OCs)
Trial: 10230741
Drug: Fluid extract
RxNorm normalized name: FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid extract of Echinacea purpurea (4 mL twice a day)
Trial: 10230741
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 mL juice twice a day)
Trial: 1867225
Drug: Oral sustained-release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sustained-release verapamil (verapamil-SR)
Trial: 6344906
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment combined with compression bandages
Trial: 27223668
Drug: Levosulpiride (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosulpiride (25-50 mg/d)
Trial: 27223668
Drug: Haloperidol (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10-20 mg/d)
Trial: 14764127
Drug: Solifenacin 5
RxNorm normalized name: solifenacin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin 5 mg once daily
Trial: 18054420
Drug: silymarin (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silymarin (0.8 g/day)
Trial: 18054420
Drug: silymarin+yacon (0.8+2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silymarin+yacon (0.8+2.4 g/day)
Trial: 18054420
Drug: silymarin+maca (0.6+0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silymarin+maca (0.6+0.2 g/day)
Trial: 18054420
Drug: maca (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maca (0.6 g/day)
Trial: 18054420
Drug: maca (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maca (high doses)
Trial: 12755242
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg prostaglandin E2 vaginal tablets
Trial: 10996361
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of CD105 with active TGFbeta1 and (a+l)TGFbeta1
Trial: 9229826
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate aerosol treatment
Trial: 23122405
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg of PPTA
Trial: 23122405
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg of PPTA
Trial: 23122405
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg of PPTA
Trial: 20187249
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy approaches to increase levels of endogenous dopamine or enhance the function of levodopa
Trial: 20187249
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy approaches to normalize basal ganglia circuitry by reducing PD-related overactivity of specific brain structures
Trial: 19667500
Drug: Venlafaxine XR
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine XR (37.5 to 225 mg once daily)
Trial: 26881208
Drug: Daily intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T) for 6 months
Trial: 26881208
Drug: Daily intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T)
Trial: 23595613
Drug: Rebamipide 100
RxNorm normalized name: Rebamipide 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebamipide 100 mg three times daily for 4 weeks
Trial: 15367828
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg/day)
Trial: 18047925
Drug: Spironolactone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25 mg/day) for 3 months
Trial: 15650042
Drug: Psychosocial counselling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial counselling intervention (three sessions with a social worker trained in Experiential Psychosocial Therapy: one before, one during, and one after the first IVF cycle)
Trial: 12395333
Drug: Tamoxifen 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 120 mg/d (TMX120)
Trial: 12395333
Drug: Tamoxifen 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 60 mg/d (TMX60)
Trial: 10092165
Drug: Muscle relaxation
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle relaxation training (30 minutes, twice a week for 10 weeks)
Trial: 7594701
Drug: cp-45 vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 45 vaccine
DrugBank: Human papillomavirus type 45 L1 capsid protein antigen (DB10312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cp-45 vaccine (10^4 or 10^5 TCID50)
Trial: 7594701
Drug: cp-45 vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 45 vaccine
DrugBank: Human papillomavirus type 45 L1 capsid protein antigen (DB10312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cp-45 vaccine (10^5 TCID50)
Trial: 6576204
Drug: Radiation doses
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation doses of less than or equal to 18 Gy
Trial: 6576204
Drug: Radiation doses
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation doses of 24 Gy
Trial: 6576204
Drug: Intensive systemic
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive systemic reinduction therapy
Trial: 30859618
Drug: Monovalent PHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent PHF vaccine administered at separate sites
Trial: 30859618
Drug: Multivalent PHF/Rabies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivalent PHF/Rabies vaccine administered at a single site
Trial: 28406122
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment (Group M)
Trial: 28406122
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser disinfection (Group L)
Trial: 28406122
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mechanical treatment and diode laser (Group M + L)
Trial: 25641925
Drug: Weight loss
RxNorm normalized name: HERBAL WEIGHT LOSS AID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight loss during neoadjuvant chemotherapy (NCT)
Trial: 25641925
Drug: Weight gain
RxNorm normalized name: Nutritional Supplement Oral Powder for Suspension [MUSCLE & WEIGHT GAINER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight gain during neoadjuvant chemotherapy (NCT)
Trial: 24835038
Drug: Enhanced depression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced depression treatment for 6 months
Trial: 19075991
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of cereal allergens
Trial: 12918893
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of docetaxel (Taxotere) and capecitabine (Xeloda)
Trial: 8732122
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release tablets of Tripterygium wilfordii (TW‐SR), 2 tablets, twice a day for 4 weeks
Trial: 8732122
Drug: Tablets of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets of Tripterygium wilfordii (TW), 2 tablets, 3 times per day for 4 weeks
Trial: 1831755
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids
Trial: 1831755
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids
Trial: 30311987
Drug: Oral oncolytic
RxNorm normalized name: Telomerase Specific Replication-competent Oncolytic Adenovirus
DrugBank: Suratadenoturev (DB18672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oncolytic treatment
Trial: 30517572
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation containing chamomile microparticles coated with chitosan
Trial: 30517572
Drug: Base formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Base formulation
Trial: 30517572
Drug: Formulation with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with microparticles
Trial: 26403703
Drug: Maternal breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal breast milk supplementation with 2g of a multinutrient supplement (Pré-Nan(®), Nestlé) added to expressed breast milk twice a day until a corrected age of 4-6 months.
Trial: 24231400
Drug: Lee Silverman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lee Silverman Voice Treatment-BIG (BIG; 16 hours over 4 weeks)
Trial: 17333159
Drug: Gemfibrozil 600
RxNorm normalized name: gemfibrozil 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil 600 mg orally twice daily for 3 days
Trial: 16279906
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron sucrose (7 mg iron/kg body weight, followed by five 200 mg infusions over 5 weeks)
Trial: 16279906
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron sulfate (100-200 mg per day for 6 weeks)
Trial: 9834991
Drug: Chest irradiation
RxNorm normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chest irradiation combined with chemotherapy
Trial: 4776883
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (2,000 international units daily for three months)
Trial: 4776883
Drug: Anticonvulsant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticonvulsant treatment
Trial: 26206641
Drug: Mupirocin ointment
RxNorm normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mupirocin ointment application (MOA)
Trial: 23328389
Drug: Treprostinil diolamine
RxNorm normalized name: treprostinil diolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treprostinil diolamine (oral sustained release tablets), chronic dosing (twice-daily)
Trial: 20977377
Drug: Monochromatic near-infrared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monochromatic near-infrared light treatment (12 sessions of 30 minutes each over 4 weeks)
Trial: 20977377
Drug: Monochromatic near-infrared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monochromatic near-infrared light treatment
Trial: 9371358
Drug: 3.375 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.375 g piperacillin-tazobactam every 6 hours
Trial: 9371358
Drug: 4.5 g
RxNorm normalized name: Zosyn 4.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g piperacillin-tazobactam every 8 hours
Trial: 3914805
Drug: CSII (Continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSII (Continuous Subcutaneous Insulin Infusion)
Trial: 3914805
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily mixed rapid and long acting insulin
Trial: 3914805
Drug: Multiple s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple s.c. injections via butterfly 5-6x daily
Trial: 30920278
Drug: Growth-mindset only
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth-mindset only treatment
Trial: 23235413
Drug: Transcranial stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial stimulation (TS) along with standard treatment (antiaggregant vascular drugs and hypocaloric diet)
Trial: 14734454
Drug: Large multivalent
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large multivalent immunogen (LMI) administered without adjuvant, one-half intradermally (i.d.) and the other half subcutaneously (s.c.) at doses of 10-, 30-, or 100-million tumor cell equivalents on weeks 0, 4, and 8.
Trial: 14625516
Drug: Soy protein
RxNorm normalized name: Soy Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy protein supplement 0.5 g/kg body mass/day
Trial: 10668490
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (3 gm daily; 1200 mg elemental calcium)
Trial: 1712206
Drug: L-deprenyl (LD)
RxNorm normalized name: L-deprenyl-D2 C-11
DrugBank: L-deprenyl-D2 C-11 (DB12650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-deprenyl (LD)
Trial: 2871818
Drug: Molsidomine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (2 mg)
Trial: 2871818
Drug: Risordan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risordan (20 mg)
Trial: 2871818
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release Trinitrin (2.5 mg)
Trial: 2871818
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release Trinitrin (5 mg)
Trial: 2871818
Drug: Lenitral (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenitral (7.5 mg)
Trial: 2871818
Drug: Langoran (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Langoran (40 mg)
Trial: 2871818
Drug: Trinitrin skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trinitrin skin patch (10 mg)
Trial: 26719492
Drug: Equal preference
RxNorm normalized name: equol, (+-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equal preference among biologics for themselves (aflibercept 30.6%, bevacizumab 36.5%, ranibizumab 32.9%)
Trial: 16885120
Drug: Procaterol HCl
RxNorm normalized name: procaterol HCl
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaterol HCl pellets capsule
Trial: 10950051
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg budesonide
Trial: 1362137
Drug: Alpidem (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpidem (75 to 150 mg daily, 25-50 mg t.i.d. for 3 weeks)
Trial: 24686825
Drug: Triadic gaze
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triadic gaze (TG) treatment twice weekly with a speech‐language pathologist for 29 sessions over 17 weeks
Trial: 23118850
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy Group (CBT)
Trial: 20880642
Drug: Natural menopausal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural menopausal supplements and diets rich in isoflavones
Trial: 20880642
Drug: Paroxetine, fluoxetine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine, fluoxetine, bupropion
Trial: 18035078
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) (48 hours)
Trial: 16192448
Drug: 30-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-microg dose of technetium-99m-labeled monodisperse albuterol aerosols with particle sizes of 1.5 microm, 3 microm, and 6 microm
Trial: 16192448
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg metered-dose inhaler (MDI) albuterol
Trial: 12270622
Drug: Moulded isomalt-based
RxNorm normalized name: Isomalt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moulded isomalt-based tablet (50 mg HCT)
Trial: 12270622
Drug: Moulded isomalt-based
RxNorm normalized name: Isomalt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moulded isomalt-based lozenge (50 mg HCT)
Trial: 12270622
Drug: Conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tablet (Dichlotride 50 mg)
Trial: 7637152
Drug: Bupivacaine-fentanyl continuous
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bupivacaine-fentanyl continuous infusion (BF-C group)
Trial: 7637152
Drug: Morphine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine bolus injection (M-S group)
Trial: 2474109
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg initially, adjusted between 1.25-20 mg)
Trial: 2474109
Drug: Ramipril plus
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril plus HCT (25 mg)
Trial: 1158003
Drug: Cream base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream base alone
Trial: 28482144
Drug: Canakinumab treatment
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab treatment
Trial: 26447149
Drug: Parenteral Nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Nutrition
Trial: 28364509
Drug: Almorexant 50
RxNorm normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Almorexant 50 mg
Trial: 28364509
Drug: Almorexant 25
RxNorm normalized name: Nemorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Almorexant 25 mg
Trial: 28364509
Drug: Almorexant (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almorexant (all doses)
Trial: 22527308
Drug: Bibrocathol 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bibrocathol 2% eye ointment
Trial: 19745175
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day encapsulated fish oil (1.2 g total omega-3: 0.7 g DHA; 0.3 g EPA)
Trial: 19745175
Drug: Placebo oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oil (combination palm and soy)
Trial: 9626787
Drug: Low-dose leucovorin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose leucovorin (20 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Trial: 9626787
Drug: High-dose leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose leucovorin (200 mg/m2/day, days 1 through 5) combined with 5-FU (400 mg/m2/day every 4 weeks)
Trial: 9626787
Drug: High-dose leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose leucovorin combined with 5-FU
Trial: 3312283
Drug: Micronized oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized oral progesterone, 200 mg daily
Trial: 29921036
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) and lattice CO2 laser treatments
Trial: 29921036
Drug: Conventional approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional approach with scar cream massage and silica gel products
Trial: 25135744
Drug: 6 SQ
RxNorm normalized name: American house dust mite allergenic extract 6 SQ-HDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 SQ HDM SLIT-tablet
Trial: 20841796
Drug: Email reminders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Email reminders focused on unrelated content (oral cancer prevention)
Trial: 18048572
Drug: Oral unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral unfractionated heparin with sodium N‐[8‐(2‐hydroxybenzoyl) amino]caprylate (salcaprozate sodium, SNAC)
Trial: 18048572
Drug: Parenterally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenterally administered unfractionated heparin
Trial: 18048572
Drug: Oral unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral unfractionated heparin with SNAC